TAIWAN LIPOSOME/S’s (NASDAQ:TLC) lock-up period is set to expire on Monday, May 20th. TAIWAN LIPOSOME/S had issued 3,750,000 shares in its initial public offering on November 21st. The total size of the offering was $21,750,000 based on an initial share price of $5.80. After the expiration of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Several research analysts have recently issued reports on TLC shares. Cantor Fitzgerald set a $11.00 target price on shares of TAIWAN LIPOSOME/S and gave the company a “buy” rating in a research note on Friday, April 5th. Zacks Investment Research raised shares of TAIWAN LIPOSOME/S from a “sell” rating to a “hold” rating in a research note on Thursday, April 11th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of TAIWAN LIPOSOME/S in a research note on Thursday, April 18th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $10.33.
Shares of TLC opened at $5.61 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.45 and a current ratio of 3.45. TAIWAN LIPOSOME/S has a twelve month low of $5.02 and a twelve month high of $11.00. The company has a market capitalization of $178.74 million and a price-to-earnings ratio of -11.94.
TAIWAN LIPOSOME/S (NASDAQ:TLC) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.19. TAIWAN LIPOSOME/S had a negative net margin of 414.31% and a negative return on equity of 150.37%. The firm had revenue of $5.11 million for the quarter, compared to analyst estimates of $3.00 million. Analysts anticipate that TAIWAN LIPOSOME/S will post -0.9 earnings per share for the current year.
An institutional investor recently bought a new position in TAIWAN LIPOSOME/S stock. Karst Peak Capital Ltd purchased a new stake in TAIWAN LIPOSOME/S (NASDAQ:TLC) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 568,965 shares of the company’s stock, valued at approximately $3,129,000. TAIWAN LIPOSOME/S makes up about 11.5% of Karst Peak Capital Ltd’s portfolio, making the stock its 3rd biggest position. Karst Peak Capital Ltd owned approximately 1.79% of TAIWAN LIPOSOME/S as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 2.17% of the company’s stock.
TAIWAN LIPOSOME/S Company Profile
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.
Featured Article: Gap Up Stocks
Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.